pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Alimta
drug
save

Alimta

Marketedupdated 3mo ago
by Lilly USA LLC
Approved
community read0 votes

🐶 often sniffed alongside

top 4
  • tagApproval10 co-mentions · 5 sources
  • drugpemetrexed5 co-mentions · 5 sources
  • drugPEMETREXED DISODIUM5 co-mentions · 5 sources
  • drugPemetrexed Disodium Intas5 co-mentions · 5 sources

indications

investigational
NSCLC

all catalysts(3)

approval · 3
May 26, 2022
approval
4y ago
PEMETREXED DISODIUM — FDA approval
Alimta
→
Apr 21, 2023
approval
3y ago
PEMETREXED DISODIUM — FDA approval
Alimta
→
Dec 15, 2025
approval
8mo ago
PEMETREXED DISODIUM — FDA approval
Alimta
→

Trials studying Alimta

  • phase3Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutationrecruitingn=300
  • phase2A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumorsrecruitingn=570
  • phase2A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumorsrecruitingn=156
  • phase3A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancerrecruitingn=398
  • phase2Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancerrecruitingn=162
  • phase3Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)active not recruitingn=453
  • phase2Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancerterminatedn=14
  • phase2A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]recruitingn=230
more trials →

News(0)

no news has mentioned this drug yet

brand
Alimta
generic
pemetrexed disodium
indication
Malignant Pleural Mesothelioma
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 17m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?